Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

Infection and Immunity

Volumn 67, Issue 5, 1999, Pages 2366-2370

  Usinger, William R ^a   Lucas, Alexander H ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G2; PNEUMOCOCCUS ANTIBODY; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL MEMBRANE; BINDING AFFINITY; MOUSE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0032903986     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.5.2366-2370.1999     Document Type: Article

References (33)

1. Alonso deVelasco, E., A. F. M. Verheul, J. Verhoef, and H. Snippe. 1995. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol. Rev. 59:591-603.
2. Amir, J., X. Liang, and D. M. Granoff. 1990. Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b. Pediatr. Res. 27:358-364.
3. Anderson, P. 1984. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 149:1034.
4. Anttila, M., J. Eskola, H. Ähman, and H. Käyhty. 1998. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. 177:1614-1621.
5. Austrian, R. 1984. Pneumococcal infections, p. 257-288. In R. Germanier (ed.), Bacterial vaccines. Academic Press, Inc., Orlando, Fla.
6. Bachmann, M. F., U. Kalinke, A. Althage, G. Freer, C Burkhart. H.-P. Roost, M. Auget. H. Hengartner, and R. M. Zinkernagel. 1997. The role of antibody concentration and avidity in antiviral protection. Science 276:2024-2027.
7. Benton, K. A., J. C. Paton, and D. E. Briles. 1997. Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2,3,4,5, and 6 are not attributable to differences in pneumolysin production. Infect. Immun. 65:1237-1244.
8. Briles, D. E., B. Crain, B. M. Gray, C. Forman, and J. Yother. 1992. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect. Immun. 60:111-116.
9. Bruyn, G. A. W., B. J. M. Zegers, and R. van Furth. 1992. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin. Infect. Dis. 14:251-262.
10. Cohn, M., and R. E. Langman. 1990. The protecton: the unit of humoral immunity selected by evolution. Immunol. Rev. 115:11-147.
11. Ellis, R. W., and D. M. Granoff. 1994. Development and clinical uses of Haemophilus b conjugate vaccines. Marcel Dekker, Inc., New York, N.Y.
12. Foote, J., and H. N. Eisen. 1995. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92:1254-1256.
13. Goldblatt, D., A. R. Pinto Vaz, and E. Miller. 1998. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1112-1115.
14. Granoff, D. M., and A. H. Lucas. 1995. Laboratory correlates of protection against Haemophilus influenzae type B disease: importance of assessment of antibody avidity and immunologic memory. Ann. N. Y. Acad. Sci. 754:278-288.
15. Granoff, D. M., P. G. Shackelford, S. J. Holmes, The Collaborative Vaccine Study Group, and A. H. Lucas. 1993. Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates: description of a new λ light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. J. Clin. Investig. 91:788-796.
16. Griswold, W. R., A. H. Lucas, J. F. Bastian, and G. Garcia. 1989. Functional affinity of antibody to the Haemophilus influenzae b polysaccharide. J. Infect. Dis. 159:1084-1087.
17. Heidelberger, M., C. M. MacLeod, and M. M. diLappi. 1948. The human antibody response to simultaneous injection of six specific polysaccharides of pneumococcus. J. Exp. Med. 88:369-372.
18. Käyhty, H., and J. Eskola. 1996. New vaccines for the prevention of pneumococcal infections. Emerg. Infect. Dis. 2:289-298.
19. Käyhty, H., H. Peltola, V. Karanko, and P. H. Mäkelä. 1983. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 147:1100.
20. Klein, D. L., and R. W. Ellis. 1997. Conjugate vaccines against Streptococcus pneumoniae, p. 503. In M. M. Levine, G. C. Woodrow, J. C. Kaper, and G. S. Cobon (ed.), New generation vaccines, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
21. Konradsen, H. B., M. Hahn-Zone, and L. Å. Hanson. 1994. Differences within mono- and dizygotic twin-pairs in spectrotypes and clones of IgG2 antibodies to pneumococcal polysaccharide type-1 and C-polysaccharide after vaccination. Scand. J. Immunol. 40:423-428.
22. Lucas, A. H., and D. M. Granoff. 1995. Functional differences in idiotypically denned IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type b polysaccharide-protein conjugates. J. Immunol. 154:4195-4202.
23. Lucas, A. H., D. M. Granoff, R. E. Mandrell, C. C. Connolly, A. S. Shan, and D. C. Powers. 1997. Oligoclonality of serum immunoglobulin G antibody responses to Streptococcus pneumoniae capsular polysaccharide serotypes 6B, 14, and 23F. Infect. Immun. 65:5103-5109.
24. Musher, D. M., B. Johnson, Jr., and D. A. Watson. 1990. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect. Immun. 58: 3871-3876.
25. Nahm, M. H., J. V. Olander, and M. Magyarlaki. 1997. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J. Infect. Dis. 176:698-703.
26. Park, M. K., Y. Sun, J. V. Olander, J. W. Hoffmann, and M. H. Nahm. 1996. The repertoire of human antibodies to the carbohydrate capsule of Streptococcus pneumoniae 6B. J. Infect. Dis. 174:75-82.
27. Pincus, S. H., A. O. Shigeoka, A. A. Moe, L. P. Ewing, and H. R. Hill. 1988. Protective efficacy of IgM monoclonal antibodies in experimental group B streptococcal infection is a function of antibody avidity. J. Immunol. 140: 2779-2785.
28. Quataert, S. A., C. S. Kirch, L. J. Q. Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
29. Robbins, J. B., R. Austrian, C.-J. Lee, S. C. Rastogi, G. Schiffman, J. Henrichsen, P. H. Mäkela, C. V. Broome, R. R. Facklam, R. H. Tiesjema, and J. C. Parke. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1136-1159.
30. Romero-Steiner, S., D. Libutti, L. B. Pais, J. Dykes, P. Anderson, J. C. Whitin, H. L. Keyserling, and G. M. Carlone. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415-422.
31. Schlesinger, Y., D. M. Granoff, and The Collaborative Vaccine Study Group. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 267:1489-1494.
32. Siber, G. R. 1994. Pneumococcal disease: prospects for a new generation of vaccines. Science 265:1385-1387.
33. Stack, A. M., R. Malley, C. M. Thompson, L. Kobzik, G. R. Siber, and A. S. Saldino. 1998. Minimum protective serum concentration of pneumococcal anti-capsular antibodies in infant rats. J. Infect. Dis. 177:986-990.